Plasma efavirenz exposure, sex, and age predict virological response in HIV-infected African children by Bienczak, A et al.
 Table 1 Demographic characteristics and model-derived PK parameters in different suppression groups. 
 
 





















































































































IM 28 6 8 3 6 
SM 21 6 -- 2 3 
USM -- -- 1 -- -- 
NRTI 
 





Zidovudine 26 6 2 4 4 
Abacavir 24 6 3 2 5 












































































Presented values are number or median (IQR) 1 
*Kruskal Wallis or Fisher’s Exact test comparing 4 groups of originally treatment-naïve children only.  2 
**Kruskal Wallis or Fisher’s Exact test comparing 5 groups including children who were treatment-3 
experienced at enrolment.  4 
†EM (extensive metabolisers) - 516GG|983TT; IM (intermediate metabolisers) - 516GG|983TC or 5 
516GT|983TT, SM (slow metabolisers) - 516TT|983TT or 516GT|983TC; USM (ultra-slow 6 
metabolisers) - 516GG|983CC;  7 
‡Data from 104 patients (91 treatment-naïve and 13 treatment-experience at enrolment) 8 
  9 
Table 2 Univariable Cox proportional hazards regression models for C12h, C24h and 
AUC, with lowest AIC values indicating the models best describing the association with 
viral non-suppression. 
PK Par 
Change in risk per 
unit increase in 
absolute exposure 
Change in risk per 
doubling of 
exposure (per unit 
increase in log 
transformed 
exposure) 
Change in risk 















p-value 0.241 < 0.0001 < 0.0001 












p-value 0.246 < 0.0001 < 0.0001 
AIC 324.67 304.18 302.82 
AUC 
[mg∙h/L] 









p-value 0.247 < 0.0001 < 0.0001 
AIC 324.04 305.70 307.74 
HR=Hazard ratio.  10 
Note: log transform was the best fitting fractional polynomial for C24h; for C12h and AUC the best 11 
fitting transform was inverse square root. However, the difference in AIC compared to log-transform 12 
was very small in both cases (+0.47 and +0.97) and so the log transform is presented above for 13 
comparability with C24h and ease of interpretation. 14 
 15 
  16 




Final Multivariate Model 
 





<0.001 0.61 (0.50-0.76) <0.001 




0.048 (see interaction below)  
Current age 
(ref. <8 years) 
 
5.45 (1.85-16.06) 0.002 (see interaction below)  
Sex and age (ref 
girl <8y) 
 
Boy <8y: 6.14 (2.01-18.77) 
Girl >8y: 16.63 (4.05-68.37) 




Boy <8y: 5.31 (1.58-17.82) 
Girl >8y: 15.82 (2.97-84.27) 






S2: 0.22 (0.06-0.77) 
S3: 0.39 (0.11-1.38) 




S2: 0.73 (0.18-2.88) 
S3: 1.04 (0.23-4.82) 




WAZ (per unit 
higher) 
0.66 (0.49-0.88) 0.005 -  
 17 
Note: as the final multivariable model identified a significant interaction between age and 18 
sex, this interaction is also presented unadjusted for other factors in the univariable column. 19 
Final model selected using backwards elimination, see methods. Interaction between 20 
continuous age and sex (p=0.01) dichotomised at the optimal age threshold for 21 
presentation. HR – hazard ratio; CI – confidence interval;  22 
 23 
  24 
Table 4 Comparison of efavirenz exposure targets and predictors of virological outcome in paediatric studies  
Reference Derived PK Targets 
Predictors of virologic failure 
n Method 
VL Target 
[copies/mL] PK Covariates 
Starr et al.22† 
AUC = 60 – 120 
mg∙h/mL 
Not analysed 
Uni: (A)* log2 bCD4% , WAZ, bVL / (B)* WAZ, bVL 




Brundage et al.17 AUC > 59 mg∙h/mL AUC 
Uni: IPAM, bVL, bCD4%, WAZ 
Multi: IPAM, bVL, AUC 
50 Cox, TSSA 400 
Hirt et al.10 
Cmin > 1.1 mg/L 
AUC > 51 mg∙h/L 








Janssens et al.21  Not analysed 
Uni: Orphan status, male gender 





Kamaya et al.19‡ Not analysed 
Uni: male gender, bCD4%<5% 





Jittamala et al.20‡ Not analysed Uni: male gender, age, adherence 202 Cox 50 
 Multi: none 
Bienczak et al. 
(this analysis) 
C12h > 1.12 mg/L 
Cmin > 0.65 mg/L 
AUC > 28 mg∙h/L 
C12h, Cmin, AUC 
Uni: male gender, age < 8 years, site, WAZ 
Multi: male gender, age < 8 years  
118 Cox 100 
† target derived based on adult data, ‡ patients treated with nevirapine or efavirenz – presented results relate to efavirenz only, *two efficacy cut-offs used: 25 
(A) 400 copies/mL, (B) 50 copies/mL; bCD4% - baseline (pre-ART) CD4 percentage, bVL – baseline (pre-ART) viral load, Cox – Cox proportional hazards 26 
regression,  IPAM – integrated pharmacokinetic adherence measure, Multi – multivariate analysis, TSSA - tree-structured survival analysis, Uni – univariate 27 
analysis, VL – viral load, WAZ – weight-for-age z-score 28 
 29 
 30 
Table 5 Comparison of previously published treatment targets for efavirenz concentrations and AUC and most 
predictive thresholds derived in this analysis. 
 C12h [mg/L] C24h [mg/L] AUC [mg∙h/L] 
Threshold 1.0 3 1.12  1.0 3 0.65 499 6022 28 
HR 6.36 6.14 3.96 6.57 3.16 3.84 5.77 
95% CI 2.53-15.96 2.64-14.27 1.73-9.03 2.86-15.10 1.39-7.16 1.56-9.44 2.28-14.58 



































Sensitivity 44.7% 50.0% 55.3% 50.0% 63.2% 78.9% 44.74% 
Specificity 91.2% 88.9% 78.5% 89.6% 67.1% 50.2% 90.23% 








93.0% 93.5% 93.4% 93.5% 93.6% 95.1% 92.95% 
HR –hazard ratio, 95% CI – 95% confidence interval, AIC – Akaike information criterion, PK – 31 
pharmacokinetic, T – cut-off target. In grey – cut-offs proposed by this analysis, in white – previously 32 
published cut-offs.  33 
 34 
